cooperation partners
-
exclusive license for the commercialization of glp-1 products in china
-
exclusive license to develop and commercialize programmed therapeutic cells in greater china
-
exclusive license for the distribution and promotion of insulin products
-
collaboration for clinical development and commercialization of mcm1 in china
-
exclusive partnership to commercialize liposomal products utilizing nanox™ in mainland china
-
priority for potential licensing or development of two ophthalmic-related disease products
-
exclusive right to develop and commercialize remitch in china
-
partnership focused on the development and commercialization of novel bi- and multi-specific antibodies in the field of immuno-oncology
-
collaboration for clinical development and commercialization of multiple biosimilars in china
-
potential licensing priorities for four inner ear disease related research products
-
investment to research and develop early stage cancer drugs